/l) in adults. 2 A similar shortening of neutropenia due to G-CSF treatment was observed in children. 3 After transplantation of allogeneic peripheral blood progenitor cells (PBPC), a reduction of neutropenia by 4-5 days was observed. 4 Diminuition of morbidity and mortality by G-CSF has been more difficult to demonstrate. One study has suggested, that patients receiving G-CSF were less likely to suffer from severe mucositis (grades 3-4) after allogeneic BMT. 5 In the case of autotransplantation, treatment with G-CSF has been associated with shortening of time spent in the hospital. 2, [6] [7] [8] The optimal time to start G-CSF after progenitor cell transplantation is less well established. In the setting of autologous PBPC tranplantation the time to neutrophil recovery was identical for patients starting treatment with G-CSF on day 0, 3 or 5. 9 The use of hematopoetic growth factors in the setting of allogeneic BMT has been hampered by several concerns, such as that G-CSF might increase the risk of chronic graft-versus-host disease. 10 Furthermore, in vitro data have suggested, that G-CSF could enhance the regrowth of leukemic cells and favor relapse of disease after BMT. 11, 12 Therefore, it seems advisable to minimize the duration of treatment with G-CSF without reducing the benefit of accelerated hematological recovery due to G-CSF.
In the present study we report our experience with delaying G-CSF treatment with respect to hematological engraftment, infectious complications and outcome after allogeneic BMT.
Patients and methods

Study population
During a period of 2 years until March 1998 we randomized 38 consecutive patients undergoing BMT to either receive G-CSF treatment starting at day 1 (group A) or at day 6 (group B) after BMT. The demographic characteristics of the two groups are summarized in Table 1 . The average age, distribution of sex, medical diagnosis, stage of disease at the time of BMT and pretransplantation characteristics were comparable in both groups (Table 1) .
Patients with acute myeloid leukemia presented in complete remission (CR, n = 11) or with residual disease (n = 3). Four patients with ALL were transplanted either in Table 1 Demographic characteristics of patients treated with daily G-CSF starting on day 1 (group A) or day 6 (group B) after allogeneic BMT Nine of 20 patients of group A and 11/18 patients of group B were seropositive for CMV prior to BMT. HLAidentical sibling donors and HLA-A/B/DRB1-identical CTLP-negative unrelated donors were equally distributed between both groups. Three out of 11 CMV-seronegative patients received a CMV-seropositive bone marrow graft in group A compared to one out of seven CMV-seronegative patients in group B.
BMT protocols
In all patients, the conditioning regimens included cyclophosphamide at a standard total dose of 120 mg/kg body weight, which was combined with fractionated total body irradiation (6 ϫ 2 Gy over 6 days in 28 patients) or with busulfan at a total dose of 16 mg/kg body weight (10 patients). VP-16 at a total dose ranging from 30 to 60 mg/kg was added in 10/20 patients of group A and in 7/18 of group B. The number of nucleated allogeneic bone marrow cells transplanted was the same in both groups ( Table 1) . Prevention of acute graft-versus-host disease was the same for all patients consisting of cyclosporin A for at least 6 months and short-course methotrexate regimen with folinic acid rescue.
G-CSF study protocol
All patients received a daily standard dose of 263 g of glycosylated lenograstim subcutaneously (Granocyte, Rhône-Poulenc Rorer, Switzerland), starting on day 1 (group A) or day 6 (group B) according to randomization. Patients were treated continuously until they reached PMN counts Ͼ1000/l for 3 consecutive days.
Supportive care
All patients received GVHD prophylaxis with short-course methothrexate (15 mg/m 2 on day ϩ1, 10 mg/m 2 , on days ϩ3, ϩ6 and ϩ11) combined with cyclosporin A (10 mg/kg/day, continous infusion, on day Ϫ1 to ϩ21, followed by oral doses three times a day for 3 to 6 months). All patients received immunoglobulin (Sandoglobuline, 0.5 mg/kg) weekly until day 40 after BMT. Platelet substitution of CMV-negative patients was done with CMVnegative single-donor platelets. Erythrocytes were substituted with leukocyte-depleted red blood cells. All blood products were irradiated with 3000 cGy. Except for P. carinii prophylaxis with trimethoprim/sulfamethoxazol, no prophylactic antibiotic, antifungal or antiviral treatment was performed. Empirical antibiotic treatment was started if the body temperature rose above 38.0°C. Patients who succumbed to a second febrile episode or who did not respond to broad-spectrum antibiotics within 3 days, received empirical antifungal treatment with amphotericin B. Two patients in group A, and one patient in group B presented with suspected hepatolienal candidiasis on the abdominal CAT scan prior to BMT. All of them were treated with fluconazole prior to and after BMT, which was continued during the whole in-patient period in two patients and substituted for amphotericin B in the third. Another patient in group A presented with suspected fungal pulmonary infiltrates prior to BMT and was treated with itraconazole during the whole transplantation period. One patient in group B presented with bronchiectasia of the lungs and was treated during the whole hospitalisation with amphotericin B. All patients were treated in reverse isolation in HEPA-filtered single rooms and received vancomycin, gentamycin and amphotericine orally for gut decontamination.
Statistical analysis and study endpoints
Statistical analysis were performed with SPSS. For unpaired data, such as the comparison of the recovery of neutrophils, the Mann-Whitney U test or the Wilcoxon rank sum test, respectively, were used. Equality of variances was tested with the Levene's test. Comparison of pro-portions were done using the 2 test, and if appropriate, the Fisher's exact test was used. Time to event data and survival data were analyzed with the log rank test.
Results
Hematological recovery
All patients showed prompt and sustained bone marrow engraftment. The recovery of PMN counts was similar whether G-CSF was started on day 1 or day 6 after BMT ( Table 2) . After 3 days with PMN counts Ͼ1000/l G-CSF was stopped. This was regularly followed by a decrease of the PMN counts. The nadir of PMNs after stopping G-CSF was 1178 Ϯ 935/l in group A and 1426 Ϯ 1158/l in group B. The nadir of PMNs after stopping G-CSF was reached at day 30.4 Ϯ 6.9 after BMT in group A, and day 30.3Ϯ5.8 in group B. The engraftment of the erythropoietic cell line was similar in both groups, as was the number of erythrocyte concentrates transfused until day 50 (Table 2) . Platelet recovery and the number of platelet transfusions were also similar in both groups (Table 2) .
Clinical parameters and infectious complications
There was no difference in overall survival in both groups (P = 0.7). In group A, three patients died: one of septicemia on day 20 after BMT, one of graft-versus-host disease 3 months after BMT and one from suicide 6 months after BMT. Of the 18 patients of group B, one patient died from pulmonary failure 1 month after unrelated HLA-identical BMT. Another patient died 6 months after BMT from infectious complications in the context of badly controlled graft-versus-host disease. No patient has relapsed so far, with a median observation time of 18 Ϯ 9.6 months for Table 2 Hematological recovery of patients treated with G-CSF starting on day 1 (group A) or day 6 (group B) after allogeneic BMT Four patients (two in each arm) were afebrile throughout the entire BMT period and did not require any antibiotic treatment. The total number of days with antibiotic treatment, and the average time to the first febrile episode were comparable in both arms. The length of the hospitalization was also similar in both groups (Table 3 ). There were five positive blood cultures in group A (two S. aureus, two SKN, and one P. aeruginosa). In group B, there was one case of SKN-related cellulitis, one case of C. difficilerelated diarrhea and one patient with positive blood cultures for anaerobes.
Episodes of presumed fungal infections, including superficial oral candidiasis requiring antifungal treatment was analyzed. Patients presenting with suspected fungal disease prior to BMT were excluded. The incidence of aplasiarelated fungal disease was comparable in both groups (Table 3) . In group A, nine out of 18 evaluable patients (50%) experienced aplasia-related fungal infections, whereas in group B, nine out of 15 patients (60%) experienced aplasia-related fungal infections (P = 0.3). The number of patients started on amphotericin B treatment and the average length of treatment with amphotericin B was also similar in both groups (Table 3) . A comparable number of patients received fluconazole, mostly because of superficial oral candidiasis.
Viral infections were common in both groups. Herpes infections of the oral cavity or the perioral region occurred in 16 out of 20 patients (80%) in group A and in all 18 patients (100%) in group B (P = 0.11). The average length Table 3 Clinical outcome of patients treated with G-CSF beginning on day 1 (group A) or day 6 (group B) after allogeneic BMT Indicates that 19 patients in group A were evaluable because of early death of one patient.
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of treatment per patient with acyclovir was comparable in both arms: 10.7 Ϯ 9.3 days in group A and 12.3 Ϯ 5.1 days in group B (P = 0.31). One patient in group B showed an asymptomatic CMV reactivation treated successfully with ganciclovir followed by foscarnet.
Graft-versus-host disease
All patients received the same prophylactic treatment including short-course methothrexate and cyclosporin A. There was no difference with respect to acute GVHD in both groups (P = 0.8). Nineteen patients in group A were evaluable for acute GVHD. Thirteen (68%) experienced acute GVHD, two of grade II and two of grade III-IV (11%). Eleven patients (58%) were treated with additional systemic immunosuppression. Of the patients in group B, 11 (61%) experienced some acute GVHD, two (11%) suffered from grade III-IV disease. Ten (56%) were treated with additional systemic immunosuppression. Acute GVHD was the primary cause of death in one patient in each group.
Toxicity
Overall toxicity and side-effects from transplant-related treatment were similar in both groups. Eight patients in each group suffered from mucositis, two in each group with grade III or IV toxicity (only grade III or IV mucositis were retained for analysis in Table 3 ). Two in each group experienced drug-related skin eruptions and one patient in group A suffered from presumed mild VOD compared to two patients in group B. One patient in group A had hemorrhage in the middle ear. No difference in reactions potentially attributable to G-CSF were noticed, except minimal subcutaneous hematoma at the injection site in most patients.
Use of G-CSF
The average G-CSF treatment time for group A was 19 Ϯ 3 days compared to 14 Ϯ 4 days for group B. The reduction of treatment time was statistically significant (P = 0.0017).
In group A, the average treatment costs for lenograstim (Granocyte) were US$2464.55 per patient, in group B US$1816.00. This represents a reduction of 26.3% of G-CSF treatment costs.
Discussion
There is sufficient evidence that the use of G-CSF after autologous BMT is beneficial with respect to PMN engraftment, duration of fever, infectious complications, antibiotic use and hospitalization. 6, 13 However, the benefit of hematopoietic growth factors is less well documented for allogeneic than for autologous stem cell transplantation. A few studies indicate the potential for enhanced PMN recovery, but other clinincal end-points have been less definitely affected by growth factors. 14, 15 Treatment with G-CSF starting on day 1 after transplantation of allogeneic PBSC seems to enhance neutrophil recovery significantly, 4 as has been reported after allogeneic BMT. 2 The routine application of G-CSF after allogeneic BMT has been confirmed in a recent guideline update by the ASCO, although with the comment, that clinical study-based evidence is weak. 16 The ECOG consortium has also recommended the use of G-CSF, keeping in mind the potential adverse effects of CSF in patients with acute myeloid leukemia, 17 in spite of lack of clinical evidence that G-CSF has any leukemiaenhancing potentials. 18 Postponing treatment with myeloid growth factors seems to bear no disadvantage in the setting of autologous stem cell grafting. 9, 19, 20 Another trial combining 22 patients undergoing autologous BMT and 53 patients treated with allogeneic BMT including various conditioning regimens and various GVH prophylaxes suggested that postponing G-CSF until day 7 did not influence hematological recovery after BMT. 21 In a recent study investigating allogeneic PBSC transplantation, the PMN recovery was compared with historical data from patients treated with allogeneic BMT. 22 The neutrophil recovery was faster in patients receiving PBSC. We speculate that, in these patients with earlier engraftment, the immediate post-transplantation use of G-CSF may be of different importance, as pretreatment with G-CSF during the stimulation phase may alter the cells' responsiveness to G-CSF in the early post-transplantation phase.
In the past, additional growth factors have been investigated for enhancement of hematological recovery after stem cell transplantation following intensive chemotherapy. [23] [24] [25] In a recent study, the addition of interleukin-3 starting on day 6 after initiating G-CSF on day 1 after autologous BMT seemed to be superior to a treatment schedule which starts with IL-3 only after G-CSF application from days 1 to 6.
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Timing of treatment with G-CSF in the phase of expansion of the myeloid cell lines seems to be more effective, than just in the early phase after transplantation.
An important characteristic of the present study is that all patients have been treated according to a standardized allogeneic BMT regimen, and thus represent a very homogenous cohort. The pretransplant conditioning regimens in both groups were very similar and all patients received the same standardized GVH prophylaxis. All except one patient in group A received bone marrow from an HLA-identical related donor or HLA-identical unrelated donor. Therefore, selection bias as well as confounding bias that might influence the engraftment of myeloid precursor cells and PMN recovery have been kept to a minimum in this study.
In a murine system, G-CSF has been suggested to influence the severity of acute GVHD. 27 There was no evidence in the present study, that the two G-CSF regimens may have a different effect on the incidence or severity of GVHD or relapse incidence.
Taken together, the present study shows that postponing treatment with G-CSF from day 1 to day 6 after allogeneic BMT in patients with matched, related or unrelated donors has no significant effect on hematopoietic engraftment and does not seem to be disadvantageous with respect to infectious complications, morbidity and mortality. Moreover, the delay of G-CSF treatment is associated with significant cost savings. G-CSF treatment after allogeneic BMT should not be initiated before day 6 after BMT, until future trials have determined a benefit of G-CSF treatment in the early posttransplantation period with respect to morbidity and mortality.
